MERCK Kommanditgesellschaft auf Aktien

XETRA MRK.DE

MERCK Kommanditgesellschaft auf Aktien Revenue for the year ending December 31, 2023: USD 23.17 B

MERCK Kommanditgesellschaft auf Aktien Revenue is USD 23.17 B for the year ending December 31, 2023, a -2.59% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • MERCK Kommanditgesellschaft auf Aktien Revenue for the year ending December 31, 2022 was USD 23.79 B, a 6.14% change year over year.
  • MERCK Kommanditgesellschaft auf Aktien Revenue for the year ending December 31, 2021 was USD 22.41 B, a 4.63% change year over year.
  • MERCK Kommanditgesellschaft auf Aktien Revenue for the year ending December 31, 2020 was USD 21.42 B, a 18.17% change year over year.
  • MERCK Kommanditgesellschaft auf Aktien Revenue for the year ending December 31, 2019 was USD 18.13 B, a 6.75% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
XETRA: MRK.DE

MERCK Kommanditgesellschaft auf Aktien

CEO Ms. Belen Garijo Lopez M.D.
IPO Date June 26, 1998
Location Germany
Headquarters Frankfurter Strasse 250
Employees 62,176
Sector Health Care
Industries
Description

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Similar companies

DB1.DE

Deutsche Börse AG

USD 235.70

1.85%

FME.DE

Fresenius Medical Care AG & Co. KGaA

USD 44.66

0.37%

BEI.DE

Beiersdorf Aktiengesellschaft

USD 127.49

-1.31%

StockViz Staff

January 15, 2025

Any question? Send us an email